Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population

Cancer

Volumn 104, Issue 9, 2005, Pages 1849-1853

  Dominguez, Francisco J ^a   Jones, Julie L ^a   Zabicki, Katherina ^a   Smith, Barbara L ^a   Gadd, Michele A ^a   Specht, Michele ^a   Kopans, Daniel B ^a   Moore, Richard H ^a   Michaelson, James S ^a   Hughes, Kevin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BRCA1 gene; BRCA2 gene; Breast neoplasm; Genetic counseling; Genetic screening; Hereditary neoplastic syndromes; Mass screening; Ovarian neoplasm; Risk assessment

Indexed keywords

ANAMNESIS; BREAST CARCINOMA; CANCER INCIDENCE; CANCER RISK; ETHNIC DIFFERENCE; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MAMMOGRAPHY; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 27244439695     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21393     Document Type: Review

References (31)

1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
2. Antoniou A, Pharoah PD, Narod S, et al. Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
3. Kriege M, Brekelmans C, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427-437.
4. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;92:1317-1325.
5. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356:1876-1881.
6. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA. 2001;286:2251-2256.
7. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998; 339:424-428.
8. McGuire V, Felberg A, Mills M, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and non-carriers of BRCA1 gene mutations. Am J Epidemiol. 2004;160:613-618.
9. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77-84.
10. Meijers-Heijboer H, Van Geel B, Van Putten WLJ, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159-164.
11. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615.
12. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
13. Hughes KS, Roche C, Campbell C, et al. Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. Breast J. 2003;9:19-25.
14. Jones JL, Hughes KS, Kopans DB, et al. Evaluation of hereditary risk in a screening mammography population. Clin Breast Cancer. 2005;6:38-44.
15. Shannon KM, Lubratovich ML, Finkelstein DM, Smith BL, Powell SN, Seiden MV. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Cancer. 2002;94:305-313.
16. Myriad Genetics, Inc. Identifying patients at risk for HBOC. Available from URL: http://www.myriadtests.com/provider/ id_hboc.htm. [accessed Spring 2004].
17. American Society of Clinical Oncology Policy Statement Update. Genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
18. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480-1490.
19. Seynaeve C, Verhoog LC, Van de Bosch LM, et al. Ipsilateral breast tumor recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer. 2004;40:1150-1158.
20. Robson M, Svahn T, McCormick B, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2. Cancer. 2004;103:44-51
21. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer. 2003;97:1601-1608.
22. Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004;101:1977-1986.
23. Stolier AJ, Fuhrman GM, Mauterer L, Bolton JS, Superneau DW. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA1 or BRCA2 mutation. Breast J. 2004;10:475-480.
24. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet. 1996;348:1189-1196.
25. Farly Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998;352:930-942.
26. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-1467.
27. Westman J, Hampel H, Bradley T. Efficacy of a touch screen computer based family cancer history questionnaire and subsequent cancer risk assessment. J Med Genet. 2000;37:354-360.
28. Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. J Chronic Dis. 1985;38:289-293.
29. Parent ME, Ghadirian P, Lacroix A, et al. The reliability of recollections of family history: implications for the medical provider. J Cancer Educ. 1997;12:114-1120.
30. Kerber RA, Slattery ML. Comparison of self-reported and data-base-linked family history of cancer data in a case control study. Am J Epidemiol. 1997;146:244-248.
31. United States Department of Health and Human Services. The health portability and accountability act of 1996 (HIP-PAA). Available from URL: http://answers.hhs.gov/ [accessed December 21, 2004].